Table 1

Baseline Characteristics of Patients in Whom Dofetilide Was Discontinued and Those Discharged on Dofetilide

Entire Cohort
(n = 114)
Dofetilide Discontinued
(n = 22)
Discharged on Dofetilide
(n = 92)
p Value
Age, yrs64.3 ± 7.763.5 ± 9.064.5 ± 7.00.59
BMI, kg/m233 ± 6.735 ± 833 ± 60.25
Race (white)108 (95)21 (95)87 (95)0.40
EF48 ± 1248 ± 1348 ± 120.86
CAD47 (41)8 (36)39 (42)0.60
Hypertension73 (64)15 (68)58 (63)0.65
HF55 (48)12 (54)43 (47)0.51
Diabetes mellitus37 (32)10 (45)27 (29)0.15
Paroxysmal atrial fibrillation27 (24)3 (14)24 (26)0.22
Creatinine, mg/dl1.0 ± 0.21.1 ± 0.21.0 ± 0.20.11
LVEDd, cm5.6 ± 1.05.5 ± 1.25.6 ± 1.00.67
LVESd, cm4.0 ± 1.04.0 ± 1.34.0 ± 1.00.99
Left atrial size, cm5.0 ± 0.85.0 ± 0.75.0 ± 0.80.86
Potassium, mEq/dl4.0 ± 0.44.0 ± 0.44.0 ± 0.30.56
Magnesium, mg/dl2.1 ± 0.61.9 ± 0.22.1 ± 0.70.24
Albumin, mg/dl3.9 ± 0.53.6 ± 0.53.9 ± 0.40.04
Right BBB9 (8)1 (4)8 (9)0.53
Left BBB5 (4)2 (9)3 (3)0.22
Interventricular conduction delay13 (11)4 (18)9 (10)0.25
Ventricular rate85 ± 2389 ± 2788 ± 220.38
QT (ms)386 ± 50.2379 ± 67387 ± 460.65
QTc (ms)446 ± 38451 ± 54445 ± 340.12
Concurrent QT-prolonging drugs32 (28)10 (44)22 (24)0.04

Values are mean ± SD or n (%).

BBB = bundle branch block; BMI = body mass index; CAD = coronary artery disease; EF = ejection fraction; HF = heart failure; LVESd = left ventricular end-systolic dimension; LVEDd = left ventricular end-diastolic dimension; QTc = corrected QT interval.